secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-241736
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines receives FDA national priority voucher for daraxonrasib
----------------------------------------------------------------------------

- FDA granted a non-transferrable voucher under the Commissioner's National Priority Voucher pilot program.
- Voucher is for daraxonrasib, the company's RAS(ON) multi-selective inhibitor.
- Announcement made on October 16, 2025; no financial terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312525241736/0001193125-25-241736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312525241736/d32252d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-241736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer